INZY · Inozyme Pharma Inc
-
-
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| ISIN | US45790W1080 |
| CurrencyCode | USD |
| Exchange | NASDAQ |
| Dividend Yield | 0.0% |
|---|---|
| Target Price | 19.17 |
| PE Ratio | None |
| Market Cap | 258M |
| Beta | 0.79 |
ABOUT
Inozyme Pharma Inc
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases in the United States. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein, which is in Phase 1/2 clinical trials for the treatment of ENPP1 and ABCC6 deficiency, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Learn More